The stock of Hims & Hers Health Inc. (NYSE:HIMS) last traded at $8.34, up 0.97% from the previous session.
HIMS stock price is now -8.25% away from the 50-day moving average and 2.10% away from the 200-day moving average. The market capitalization of the company currently stands at $1.76B.
With the price target of $10, Robert W. Baird recently initiated with Neutral rating for Hims & Hers Health Inc. (NYSE: HIMS).
In other news, Dudum Andrew, Chief Executive Officer sold 23,800 shares of the company’s stock on Jul 19. The stock was sold for $215,607 at an average price of $9.06. Upon completion of the transaction, the Chief Executive Officer now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 18, Chief Executive Officer Dudum Andrew sold 64,469 shares of the business’s stock. A total of $588,531 was realized by selling the stock at an average price of $9.13. Insiders disposed of 11,393,027 shares of company stock worth roughly $95.02 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HIMS stock. A new stake in Hims & Hers Health Inc. shares was purchased by SAMLYN CAPITAL, LLC during the first quarter worth $14,621,000. DRIEHAUS CAPITAL MANAGEMENT LLC invested $13,955,000 in shares of HIMS during the first quarter. In the first quarter, PRUDENTIAL FINANCIAL INC acquired a new stake in Hims & Hers Health Inc. valued at approximately $7,309,000. BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in HIMS for approximately $4,891,000. AMERIPRISE FINANCIAL INC purchased a new stake in HIMS valued at around $4,411,000 in the second quarter. In total, there are 225 active investors with 58.20% ownership of the company’s stock.
During the past 12 months, Hims & Hers Health Inc. has had a low of $4.01 and a high of $12.34. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.00, and a quick ratio of 3.60. The fifty day moving average price for HIMS is $9.04 and a two-hundred day moving average price translates $8.18 for the stock.
The latest earnings results from Hims & Hers Health Inc. (NYSE: HIMS) was released for Mar, 2023. According to the Household & Personal Products Company, earnings per share came in at -$0.05, beating analysts’ expectations of -$0.07 by 0.02. This compares to -$0.08 EPS in the same period last year. The net profit margin was -9.70% and return on equity was -19.00% for HIMS. The company reported revenue of $190.77 million for the quarter, compared to $101.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 88.3 percent. For the current quarter, analysts expect HIMS to generate $204.91M in revenue.
Hims & Hers Health Inc.(HIMS) Company Profile
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company’s curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
